UNSPSC 51285903: Cilastatin sodium

This classification denotes a protease inhibitor with the molecular formula C16H24N2O5S.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5428WXZ74M, chemically known as 2-heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, monosodium salt, (r-(r*,s*-(z)))- but more generally known as cilastatin sodium, which bears US NIH Compound Identifier 5282480.

European Medicines Agency schedules Cilastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01295MIG. Most nations schedule cilastatin sodium under HS 29309016. SMILES:. As of Q4 2014, CILASTATIN SODIUM remains the US FDA Preferred Term for this commodity.. Cilastatin sodium bears US NLM identifiers UMLS ID C0282395 and NCI Concept Code C65329.

UNSPSC 51285903 Cilastatin sodium is a Commodity code for a pharmaceutical ingredient used in combination antibiotic formulations, but the recent state and local opportunities tagged under this code do not reflect procurement of cilastatin sodium itself. Instead, the opportunities show state and local health agencies acquiring finished pharmaceutical products — antibiotic tablets, naloxone, and drug deactivation systems — through piggyback contracts and competitive bids. The mismatch between the code's nominal scope and the actual solicitations suggests limited or misclassified activity under this specific commodity code in current state and local procurement records.

The two recent opportunities on file are an Illinois Department of Public Health piggyback pharmaceutical warehouse award (Solicitation 26482DPHPREPDB53392, completed August 2026 with Chartwell Rx LLC for $2,999,999.11 over three years) and a Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, posted June 2026 with a response deadline of July 26, 2023). Neither opportunity explicitly names cilastatin sodium as a line item. The state and local buying pattern under this code, to the extent visible in recent postings, reflects pharmaceutical supply through established consortium vehicles and county health procurement channels, but the specific commodity this code nominally describes does not appear in these recent awards.